Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Genmab Ord Shs GNMSF

Healthcare Biotechnology
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA... see more

Recent & Breaking News (OTCPK:GNMSF)

Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates

Benzinga.com  May 1, 2018

Genmab A/S webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference

PR Newswire March 26, 2018

International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 22, 2018

PR Newswire March 21, 2018

Genmab A/S to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on March 22, 2018

PR Newswire March 21, 2018

Genmab 2017 Annual Report

GlobeNewswire February 21, 2018

Genmab Announces 2017 Net Sales Figures for DARZALEX® (Daratumumab)

GlobeNewswire January 23, 2018

Genmab Announces Novartis’ Intention to Transition Arzerra® (ofatumumab) from Commercial Availability to Limited Availability via Compassionate Use Programs for the Treatment of CLL in Non-US Markets

GlobeNewswire January 22, 2018

U.S. FDA Grants Priority Review for Daratumumab in Front Line Multiple Myeloma

GlobeNewswire January 19, 2018

Major Shareholder Announcement

GlobeNewswire January 9, 2018

Genmab Achieves USD 20 Million Milestone in Daratumumab Collaboration with Janssen and Updates Financial Guidance

GlobeNewswire November 29, 2017

Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Front Line Multiple Myeloma

GlobeNewswire November 21, 2017

Genmab Announces European Regulatory Submission for Daratumumab in Front Line Multiple Myeloma

GlobeNewswire November 21, 2017

Genmab Achieves USD 50 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen

GlobeNewswire November 16, 2017

Genmab Achieves USD 25 Million Milestone for First Commercial Sale of DARZALEX® (daratumumab) in Japan and Updates Financial Guidance

GlobeNewswire November 14, 2017

Major Shareholder Announcement

GlobeNewswire November 9, 2017

Genmab Announces Financial Results for the First Nine Months of 2017

GlobeNewswire November 8, 2017

Genmab Announces Additional Information Concerning Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2017

GlobeNewswire October 24, 2017

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2017

GlobeNewswire October 17, 2017

Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer

GlobeNewswire October 10, 2017

Genmab Announces Approval of DARZALEX® (daratumumab) for Relapsed or Refractory Multiple Myeloma in Japan

GlobeNewswire September 27, 2017